Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
Medical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
J Biochem Mol Toxicol. 2021 May;35(5):e22736. doi: 10.1002/jbt.22736. Epub 2021 Jan 29.
The field of nanotechnology offers great opportunities for cancer therapy.
This study aimed to compare the therapeutic impact of Zn oxide nanoparticles (ZnO NPs) and thymoquinone (TQ) alone or as cotherapy in Ehrlich ascites carcinoma (EAC) induced in mice.
This study was performed on 75 female albino mice divided into Group I: EAC-bearing control group, Group II: EAC treated with TQ, Group III: EAC treated with low-dose ZnO NPs, Group IV: EAC treated with high-dose ZnO NPs, Group V: EAC treated with TQ and low-dose ZnO NPs. All groups were subjected to measurement of cell viability, ascites fluid volume, Bcl2 protein expression by Western blot analysis, cyclooxygenase 2 (COX2) gene expression by a real-time polymerase chain reaction, enzyme-linked immunosorbent assay levels of Beclin 1, interferon γ (INFγ), interleukin 13 (IL-13), and estimation of Zn concentrations in EAC cells and liver homogenate to evaluate its toxicity.
Cotherapy has an efficient anticancer effect by enhancing apoptosis and autophagy, resulting in reducing tumor cell viability and ascites fluid volume together with downregulation of Bcl2 protein expression. This cotherapy increases Beclin 1 and INFγ and decreases IL-13. ZnO NPs upregulate COX2 expression, whereas TQ downregulates its expression. High-dose ZnO NPs have more toxic effects on liver enzymes. Using TQ together with ZnO NPs can eliminate ZnO NPs liver toxicity.
The cotherapy has an efficient anticancer effect by enhancing apoptosis and autophagy. High-dose ZnO NPs have more toxic effects on liver enzymes. Using TQ together with ZnO NPs can eliminate ZnO NP liver toxicity.
纳米技术领域为癌症治疗提供了巨大的机会。
本研究旨在比较氧化锌纳米粒子（ZnO NPs）和百里醌（TQ）单独或作为联合治疗在诱导的艾氏腹水癌（EAC）小鼠中的治疗效果。
本研究共纳入 75 只雌性白化小鼠，分为 5 组：I 组：EAC 荷瘤对照组；II 组：EAC 给予 TQ 治疗组；III 组：EAC 给予低剂量 ZnO NPs 治疗组；IV 组：EAC 给予高剂量 ZnO NPs 治疗组；V 组：EAC 给予 TQ 和低剂量 ZnO NPs 联合治疗组。所有组均进行细胞活力、腹水体积测量，Western blot 分析检测 Bcl2 蛋白表达，实时聚合酶链反应检测环氧化酶 2（COX2）基因表达，酶联免疫吸附测定法检测 Beclin 1、干扰素 γ（INFγ）、白细胞介素 13（IL-13）水平，并评估 EAC 细胞和肝匀浆中的 Zn 浓度以评估其毒性。
联合治疗通过增强细胞凋亡和自噬发挥有效的抗癌作用，从而降低肿瘤细胞活力和腹水体积，同时下调 Bcl2 蛋白表达。这种联合治疗还能增加 Beclin 1 和 INFγ，减少 IL-13。ZnO NPs 上调 COX2 表达，而 TQ 则下调其表达。高剂量 ZnO NPs 对肝酶的毒性作用更大。使用 TQ 与 ZnO NPs 联合治疗可消除 ZnO NPs 的肝毒性。
联合治疗通过增强细胞凋亡和自噬发挥有效的抗癌作用。高剂量 ZnO NPs 对肝酶的毒性作用更大。使用 TQ 与 ZnO NPs 联合治疗可消除 ZnO NPs 的肝毒性。
